Helicobacter pylori Infection and Gastric Cancer - For Want of More Outcomes

JAMA

Volumn 291, Issue 2, 2004, Pages 244-245

  Parsonnet, Julie ^a,c   Forman, David ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTERIUM IDENTIFICATION; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; EDITORIAL; ERADICATION THERAPY; FOLLOW UP; HEALTH CARE COST; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MASS SCREENING; MEDICAL DECISION MAKING; PRECANCER; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; STOMACH CANCER;

EID: 0347723714     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.2.244     Document Type: Editorial

References (13)

1. International Agency for Research on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter pylori: Views and Expert Opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, France: IARC Press; 1994: 177-240.
2. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347-353.
3. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-the Maastricht 2-2000 consensus report. Aliment Pharmacol Ther. 2002;16:167-180.
4. Hunt R, Thomson AB. Canadian Helicobacter pylori consensus conference. Can J Gastroenterol. 1998;12:31-41.
5. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65-69.
6. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC CancerBase No. 5. Lyon, France: IARC Press; 2001. Available at: http://www-dep.iarc.fr/globocan/globocan.htm. Accessibility verified December 17, 2003.
7. Fendrick AM, Chernew ME, Hirth RA, Bloom BS, Bandekar RR, Scheiman JM. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer. Arch Intern Med. 1999;159:142-148.
8. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet. 1996;348:150-154.
9. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881-1888.
10. Wong BC-Y, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187-194.
11. Correa P, Cuello C, Duque E, et al. Gastric cancer in Colombia, III: natural history of precursor lesions. J Natl Cancer Inst. 1976;57:1027-1035.
12. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784-789.
13. Ley C, Mohar A, Guarner J, et al. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. Cancer Epidemiol Biomarkers Prev. 2001;10:107-112.